Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CSPC Pharmaceutical Group ( (HK:1093) ) just unveiled an announcement.
CSPC Pharmaceutical Group has announced that its independently developed SYH2061 Injection, a double-stranded small interfering RNA drug, has received approval from China’s National Medical Products Administration for clinical trials. This drug, targeting complement component C5, is designed for treating IgA nephropathy and other complement-mediated diseases, offering long-lasting therapeutic effects and a promising clinical development value due to its superior pharmacological activity and safety profile.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$10.00 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited, incorporated in Hong Kong, operates in the pharmaceutical industry, focusing on the development and production of innovative drugs. The company is known for its research and development of new chemical drugs and has a market focus on addressing unmet medical needs.
Average Trading Volume: 171,000,435
Technical Sentiment Signal: Buy
Current Market Cap: HK$97.32B
For a thorough assessment of 1093 stock, go to TipRanks’ Stock Analysis page.